Cabozantinib and Pembrolizumab in Metastatic Pancreas

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Joseph Kim
Study ID
NCT05052723
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
  • Pembrolizumab — DRUG
    Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

Study Details

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Key Dates

Start date
Jan 4, 2022
Status verified
Nov 2025
Primary completion
Nov 5, 2024
Completion
Nov 5, 2024

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib and pembrolizumab

Primary Outcome Measure

Progression-free Survival [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kentucky Markey Cancer CenterLexingtonKentucky40536-

Related coverage on Hipa.ai

Find similar trials in Lexington, KY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Kentucky Markey Cancer Center· Lexington, KY

Related Studies